Astellas Takes First Steps In India With Prograf
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas Pharma said April 12 that its Indian subsidiary has commenced marketing immunosuppressant Prograf (tacrolimus), its flagship product, in India, in the company's first stab at the world's second most populous country